ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Titan Pharmaceuticals Inc

Titan Pharmaceuticals Inc (TTNP)

7.01
-0.37
( -5.01% )
Updated: 12:24:20

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
7.01
Bid
7.00
Ask
7.21
Volume
3,991
6.98 Day's Range 7.37
5.00 52 Week Range 16.902
Market Cap
Previous Close
7.38
Open
7.37
Last Trade
49
@
7.1334
Last Trade Time
12:24:41
Financial Volume
$ 28,624
VWAP
7.172
Average Volume (3m)
21,674
Shares Outstanding
781,503
Dividend Yield
-
PE Ratio
-0.55
Earnings Per Share (EPS)
-13.06
Revenue
557k
Net Profit
-10.21M

About Titan Pharmaceuticals Inc

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a s... Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Titan Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TTNP. The last closing price for Titan Pharmaceuticals was $7.38. Over the last year, Titan Pharmaceuticals shares have traded in a share price range of $ 5.00 to $ 16.902.

Titan Pharmaceuticals currently has 781,503 shares outstanding. The market capitalization of Titan Pharmaceuticals is $5.60 million. Titan Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.55.

TTNP Latest News

Form 8-K - Current report

false 0000910267 0000910267 2024-01-24 2024-01-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares  ...

Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that by letter dated January 24, 2024, the...

Form 8-K - Current report

false 0000910267 0000910267 2024-01-11 2024-01-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares  ...

Form 8-K - Current report

false --12-31 0000910267 0000910267 2024-01-08 2024-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares    ...

Form 8-K - Current report

false 0000910267 0000910267 2023-12-27 2023-12-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares  ...

Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a...

Form DEF 14A - Other definitive proxy statements

      UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549   SCHEDULE 14A (Rule 14a-101)   INFORMATION REQUIRED IN PROXY STATEMENTSCHEDULE 14A...

Form PRE 14A - Other preliminary proxy statements

      UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549   SCHEDULE 14A (Rule 14a-101)   INFORMATION REQUIRED IN PROXY STATEMENTSCHEDULE 14A...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.375.572289156636.648.296.28226627.22130747CS
4-0.88-11.15335868197.899.296.28124887.81678298CS
12-1.654-19.09048938138.6649.3525.25216747.70708779CS
26-2.302-24.7207903789.31211.45356377.41792645CS
52-7.19-50.633802816914.216.90254387810.18008459CS
156-48.79-87.437275985755.862516341723.8628936CS
260-1096.99-99.36503623191104130854150818137.04277396CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 21.895
(360.95%)
19.51M
XLOXilio Therapeutics Inc
$ 1.58
(147.26%)
25.85M
KYCHKeyarch Acquisition Corporation
$ 12.18
(73.87%)
106.56k
BDRXBiodexa Pharmaceuticals PLC
$ 1.4342
(66.96%)
77.37M
CEROCERo Therapeutics Holdings Inc
$ 2.52
(54.60%)
6.87M
PMECPrimech Holdings Ltd
$ 1.50
(-61.34%)
4.76M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.2001
(-38.79%)
10.88M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
GMDAGamida Cell Ltd
$ 0.038899
(-34.29%)
57.08M
UGROUrban Gro Inc
$ 1.3799
(-23.97%)
404.04k
NKLANikola Corporation
$ 1.005
(10.55%)
113.8M
BDRXBiodexa Pharmaceuticals PLC
$ 1.4342
(66.96%)
77.37M
AKANAkanda Corporation
$ 0.1856
(12.55%)
59.75M
GMDAGamida Cell Ltd
$ 0.038899
(-34.29%)
57.08M
MARAMarathon Digital Holdings Inc
$ 23.78
(7.75%)
54.34M

TTNP Discussion

View Posts
TRUISM TRUISM 3 months ago
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

LINK


SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective following the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”).

The Company's stockholders approved the reverse stock split at a Special Meeting of Stockholders on December 27, 2023. The Company’s shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market following the filing of the Amendment, which is intended go effective on January 9, 2024.

As a result of the reverse split, each 20 shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.001 per share.

The Company will not issue any fractional shares in connection with the reverse stock split. Instead, the number of shares will be rounded up to the next whole number. The reverse stock split will not modify the rights or preferences of the common stock.

Immediately after the reverse split becomes effective, there will be approximately 781,503 shares of common stock issued and outstanding. The common shares will trade under a new CUSIP number, 888314705, and continue to trade under the symbol “TTNP.” All stock options and warrants of the Company outstanding immediately prior to the reverse stock split will be proportionally adjusted.

The Company has appointed its transfer agent, Continental Stock Transfer & Trust Company (“Continental”), to act as exchange agent for the reverse stock split.

Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to brokers' particular processes.

Continental can be reached at (212) 509-4000.



TRUISM
👍️0
Monksdream Monksdream 4 months ago
TTNP new 52 week low
👍️0
Monksdream Monksdream 5 months ago
TTNP new 52 week low
👍️0
TRUISM TRUISM 7 months ago
UNVEILING TITAN PHARMACEUTICALS (TTNP)'s VALUE: IS IT REALLY PRICED RIGHT? A COMPREHENSIVE GUIDE
By GuruFocus Research-August 28, 2023
LINK



Titan Pharmaceuticals Inc (NASDAQ:TTNP) experienced a loss of -8.52% in its daily trading and a 3-month loss of -30.01%. With a Loss Per Share of $0.57, the question arises: is the stock significantly overvalued? This article seeks to explore this valuation question by providing an in-depth analysis. Let's dive in.


Company Introduction


* Warning! GuruFocus has detected 7 Warning Signs with TTNP. Click here to check it out.

* TTNP 30-Year Financial Data

* The intrinsic value of TTNP


Titan Pharmaceuticals Inc is a pharmaceutical company that develops therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura. This platform is used for the treatment of select chronic diseases where steady state delivery of a drug provides efficacy and/or safety benefits.

The company's first product based on ProNeura technology, the Probuphine (buprenorphine) implant, has been approved in the United States, Canada, and the European Union for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

At a price of $0.5 per share, Titan Pharmaceuticals (NASDAQ:TTNP) has a market cap of $7.60 million. However, the GF Value, an estimation of its fair value, stands at $0.01, indicating that the stock may be
significantly overvalued.


Understanding GF Value


The GF Value represents the current intrinsic value of a stock, derived from our proprietary method. This value is calculated based on historical multiples, GuruFocus adjustment factor based on the company's past returns and growth, and future estimates of business performance. In the case of Titan Pharmaceuticals (NASDAQ:TTNP), the stock appears to be significantly overvalued based on the GF Value calculation.

Because Titan Pharmaceuticals (NASDAQ:TTNP) is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth.


Financial Strength


Investing in companies with poor financial strength carries a higher risk of permanent loss of capital. It's essential to review a company's financial strength before deciding whether to buy its stock. Titan Pharmaceuticals has a cash-to-debt ratio of 0.82, which is worse than 81.53% of companies in the Biotechnology industry. This indicates that the financial strength of Titan Pharmaceuticals is poor.


Profitability and Growth


Companies that have been consistently profitable over the long term offer less risk for investors. Titan Pharmaceuticals has been profitable 2 over the past 10 years. However, its operating margin is -15248.21%, which ranks worse than 92.93% of companies in the Biotechnology industry, indicating poor profitability.


Growth is a crucial factor in the valuation of a company. Titan Pharmaceuticals's 3-year average revenue growth rate is worse than 98.95% of companies in the Biotechnology industry. However, its 3-year average EBITDA growth rate is 55%, which ranks better than 92.63% of companies in the industry.


ROIC vs WACC


Comparing a company's return on invested capital (ROIC) and the weighted cost of capital (WACC) is another way to assess its profitability. For the past 12 months, Titan Pharmaceuticals's ROIC is -669.31, and its WACC is 12.15.


Conclusion

In conclusion, the stock of Titan Pharmaceuticals (NASDAQ:TTNP) appears to be significantly overvalued. The company's financial condition is poor, and its profitability is weak. However, its growth ranks better than 92.63% of companies in the Biotechnology industry.

=============







TRUISM
👍️0
TRUISM TRUISM 7 months ago
Subsequent Events



We have evaluated events that have occurred after June 30, 2023 and through the date that our condensed financial statements are issued.




In July 2023, we entered into an asset purchase agreement, or the Asset Purchase Agreement, with Fedson for the sale of certain ProNeura assets including our portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology, or ProNeura Assets.

Our addiction portfolio consists of the Probuphine and Nalmefene implant programs. The ProNeura Assets constitute only a portion of our assets.

Under the terms of the Asset Purchase Agreement, Fedson will purchase the ProNeura Assets for an upfront purchase price of $2 million ($1 million at closing, $1 million to be held in escrow pending completion of certain conditions) with potential milestone payments to us of up to $50 million on future net sales of the products.

We will also receive certain royalties on future net sales of the products. As further consideration, Fedson will assume all liabilities related to a pending employment claim against us. The transaction is expected to close shortly following the signing of the Asset Purchase Agreement, subject to the satisfaction of customary closing conditions.

In July 2023, we received $250,000 in funding in exchange for the issuance of an unsecured promissory note for that principal amount to David E. Lazar, our Chief Executive Officer and chairman of our Board of Directors (the “Lazar Promissory Note”). Pursuant to the Lazar Promissory Note, the principal amount will accrue interest at a rate of the Prime Rate + 2.00% per annum, and all principal and accrued interest will be due and payable on the earlier of January 1, 2024 or such time as we receive debt or equity financing or proceeds in excess of $500,000 from the aforementioned transaction with Fedson.

In July 2023, we granted, pursuant to our Fifth Amended and Restated 2015 Omnibus Equity Incentive Plan, and as approved by our Board of Directors, an aggregate of 450,000 shares of fully vested unrestricted common stock to six members of the Board of Directors and one member of the management team.

In August 2023, we received $500,000 in funding in exchange for the issuance of a convertible promissory note for that principal amount to Choong Choon Hau (the “Hau Promissory Note”). Pursuant to the Hau Promissory Note, the principal amount will accrue interest at a rate of 10% per annum and will be payable monthly.

All principal and accrued interest shall be due and payable on January 1, 2024, unless extended as provided.

All or part of the Hau Promissory Note can be converted into our common stock at a conversion price of $0.5287 per share from time to time following the issuance date and ending on the maturity date.






TRUISM
👍️0
Monksdream Monksdream 7 months ago
TTNP new 52 week low
👍️0
AJ Freely AJ Freely 8 months ago
$TTNP - Up 36% Pre-Market/ Current Price $0.60
Announces Sale of Certain ProNeura Assets
👍️0
Monksdream Monksdream 8 months ago
TTNP new 52 week low
👍️0
Monksdream Monksdream 9 months ago
TTNP new 52 week low
👍️0
TRUISM TRUISM 9 months ago
DEA EXTENDS TELEMEDICINE OPTION FOR PRESCRIBING CONTROLLED MEDICATION
By Arielle Zionts July 03, 2023
ARTICLE


Telehealth rules, which were created during the pandemic, allowed for the prescribing of controlled substances without an in-person visit, will stay in place until November 11.







Federal regulators want most patients to see a health care provider in person before receiving prescriptions for potentially addictive medicines through telehealth — something that hasn’t been required in more than three years.

During the COVID-19 public health emergency, the Drug Enforcement Administration allowed doctors and other health care providers to prescribe controlled medicine during telehealth appointments without examining the patient in person. The emergency declaration ended May 13, and in February, the agency proposed new rules that would require providers to see patients at least once in person before prescribing many of those drugs during telehealth visits.

Controlled medications include many stimulants, sedatives, opioid painkillers, and anabolic steroids.




TRUISM
👍️0
TRUISM TRUISM 9 months ago
A FIRST-OF-ITS-KIND TRIAL STUDIES THE USE OF INJECTABLE BUPRENORPHINE TO TREAT METHAMPHETAMINE USE DISORDER AND OPIOD CO-USE
JUNE 28, 2023
ARTICLE




OAKLAND, Calif., June 28, 2023 /PRNewswire/ -- Investigators at Alameda Health System's (AHS) Bridge Clinic are participating in a new, six-city trial of injectable buprenorphine for the treatment of methamphetamine use disorder in adults who also use opioids. This is the first study to investigate the drug's efficacy in treating the two co-addictions simultaneously.

"People who use methamphetamine are involved in over half of all overdose deaths and there is a desperate need to find effective treatments for this patient population," said Erik Anderson, MD, principal investigator at AHS and Associate Medical Director of the Bridge Program. "Many patients use opioids in addition to methamphetamine, and examining treatment options for people using multiple substances is particularly important."

While buprenorphine has been used to treat opioid use disorder since 2002, there are currently no FDA-approved treatments for methamphetamine use disorder or methamphetamine use disorder together with opioid co-use.

The first-of-its-kind trial, available locally at AHS's Bridge Clinic at the Wilma Chan Highland Hospital Campus in Oakland, CA, is a 12-week randomized, double-blind, placebo-controlled study. The Bridge Clinic hopes to enroll 41 of the 246 participants to be recruited nationwide over the next two years.

The study is designated for those with moderate to severe methamphetamine use disorder coupled with mild opioid use disorder or opioid misuse. It is funded by the National Institute on Drug Abuse, part of the National Institutes of Health, and the Helping to End Addiction Long-term (HEAL) Initiative.

"Using buprenorphine as a treatment for methamphetamine use disorder and opioid co-use is a promising option for this high-risk patient population. Our hope is that the extended-release buprenorphine formulation will help patients use less methamphetamine and improve their quality of life," said Anderson.

To be considered for the study, participants must be seeking treatment for methamphetamine use disorder and opioid co-use, be 18-65 in age, and be able to attend twice-weekly outpatient clinic visits. The trial evaluates patients with twice-weekly urine drug screens as well as self-reported frequency of methamphetamine and opioid co-use.

In addition to AHS's Bridge Clinic, participating institutions include: University of Texas Southwestern Medical Center, University of California Los Angeles, Comprehensive Options for Drug Addiction (CODA), Oklahoma State University Center for Health Sciences, and the University of Washington Harborview Medical Center.



TRUISM
👍️0
TRUISM TRUISM 9 months ago
OVER 40% OF U.S. PHARMACIES REPORT NO BUPRENORPHINE IN STOCK, ACCORDING TO NEW PEER-REVIEWED STUDY FROM BICYCLE HEALTH PUBLISHED IN JAMA NETWORK OPEN
Bicycle Health-June 7, 2023
LINK





Florida pharmacies were least likely to have stock (37.1%), while Washington State pharmacies were most likely (83.9%)



Availability of buprenorphine for opioid use addiction in the United States by county






BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Bicycle Health, the leading telehealth provider of integrated medical and behavioral health care for opioid use disorder (OUD) in the United States, announced new research published in JAMA Network Open that highlights the limitations of buprenorphine availability in pharmacies across America.

Medications for opioid use disorder (MOUD) – including buprenorphine – are widely considered to be a gold-standard of care for OUD. Adherence to MOUD has been shown to reduce ER visits, non-fatal drug overdoses, and healthcare costs. A 2019 study in the Journal of Substance Abuse Treatment found that 3.6% of patients who were adherent to MOUD experienced a nonfatal drug-related overdose, compared to 13.2% of MOUD patients who were non-adherent.

In spite of the success of MOUD with buprenorphine, access to the medication continues to be a challenge for patients and their providers. This peer-reviewed study showed that 42.1% of the nearly 5,300 unique retail pharmacies contacted by Bicycle Health’s team on behalf of its patients did not report buprenorphine stock at the time of the request. Importantly, access to buprenorphine stock varied heavily depending on the state the patient resided in or type of pharmacy queried.

/



Key findings include:

* Pharmacy chains were more likely to have buprenorphine stock, with 61.6% of chain pharmacies reporting availability vs. 45.3% of independent pharmacies;

* Despite being more likely to have buprenorphine stock, there was still significant variability across chain pharmacy locations, based on chains where more than 40 locations reported stock;

* Over the course of this study, Bicycle Health made the most buprenorphine stock inquiries on behalf of patients to CVS and Walgreens locations. Buprenorphine availability was reported 59.7% and 70.3% of the time, respectively;

* Buprenorphine availability varied widely across the 32 states included in this study. Of states with more than 100 pharmacies queried, Florida locations were least likely to have stock (37.1%) and Washington State locations were most likely to have stock (83.9%);

* Over the course of this study, Bicycle Health made the most buprenorphine stock inquiries on behalf of patients in Florida and California. Buprenorphine availability was reported 37.1% and 46.8% of the time, respectively.


A full summary of the key outcomes and insights from the research are available online HERE in Bicycle Health’s resource center for strategic partners.

“Buprenorphine is a critical tool in the fight against the opioid overdose epidemic, but to be safely and effectively administered to patients with OUD, they must have consistent, timely, and convenient access,” said Bicycle Health’s Director of Research Scott G. Weiner, MD, MPH. “This study highlights how medication availability still represents a major barrier to care for many of Bicycle Health’s patients – as well as others seeking MOUD treatment across the United States.”

“At Bicycle Health, we talk a lot about defiant hope, which is essentially the need to stay upbeat and hopeful, even when it feels like we cannot help enough people, or that too few people care about our patients. Seeing this research published in JAMA is a ‘defiant hope day’ for me, because it means this issue will get the attention it deserves,” said Ankit Gupta, Bicycle Health’s Founder and CEO. “The responses we’ve gotten from some of the nation’s leading pharmacies have been inspiring, with their leaders pledging to partner with us to do better for patients long-term.”

Gupta continued, “This mission we’re on, to end opioid use disorder and increase access to treatment, needs an army of advocates working together if we’re going to overcome this epidemic. I’m grateful to see this research published and for the opportunities it’s creating for us to accelerate our mission in partnership with major pharmacies.”

"This data helps illustrate a major gap in our ability to care for patients with OUD, but the good news is it's a problem with a clear solution, “said Brian Clear, Bicycle Health’s Chief Medical Officer. “We've already had a positive response and commitment to improve stock rates from pharmacies."

The stigma associated with opioid use, the cost of in-person treatment options, and the lack of absence of telehealth treatment programs prior to the COVID public health emergency have all been consistent impediments in efforts to expand access to MOUD treatment with buprenorphine. As the Drug Enforcement Administration (DEA) looks to outline the regulations for prescribing via telehealth and continues setting stocking limits for buprenorphine, understanding the role these drugs play in addressing opioid use disorder is an important consideration. Bicycle Health’s evidence-based, clinically proven virtual care model is helping to increase access to these life-saving medications and address the opioid overdose epidemic head-on.

Bicycle Health is committed to working alongside America’s leading pharmacies, policymakers, and regulators to ensure patients across this country can safely and conveniently access the medications they need to maintain a healthy recovery.


About Bicycle Health

Bicycle Health is the leading telehealth provider of medications for opioid use disorder (MOUD) in the United States, offering an evidence-based clinical care model that includes FDA-approved Medications for Addiction Treatment (MAT), access to a highly-trained team of medical experts, therapy, a customized treatment plan, and peer support groups.

Bicycle Health’s mission is to address the country’s number one public health crisis by helping to reduce stigmas associated with opioid addiction and providing access to affordable, convenient, and confidential teleMOUD treatment for individuals in need. The company’s “whole person” approach to treatment encourages patients to focus on their life passions and goals, which has been shown to play a vital role in recovery. For more information, visit www.bicyclehealth.com.





TRUISM
👍️0
TRUISM TRUISM 9 months ago
ONLY 1 IN 4 ADOLESCENT TREATMENT FACILITIES OFFER BUPRENORPHINE FOR OPIOD USE DISORDER
JUNE 13, 2023
LINK





NIH-funded study indicates substantial need to expand access to evidence-based treatment among young people


Peer-Reviewed Publication



Only 1 in 4 residential addiction treatment facilities caring for U.S. adolescents under 18 years old offer buprenorphine, a medication used to treat opioid use disorder, according to a NEW STUDY Only 1 in 8 offer buprenorphine for ongoing treatment. These findings highlight a significant gap in access to evidence-based addiction treatment among young people. Published in JAMA, this study was supported by the National Institute on Drug Abuse (NIDA) and the National Center for Advancing Translational Sciences (NCATS), both part of the National Institutes of Health, and led by researchers at Oregon Health & Science University (OHSU).

There has been a dramatic rise in overdose deaths among young people aged 14-18 in recent years, likely driven by illicit counterfeit pills containing fentanyl. For those with opioid use disorder, medications are the most effective treatment options for preventing both return to opioid use and overdose deaths. Buprenorphine is the only medication for opioid use disorder that is approved by the U.S. Food and Drug Administration for use in people aged 16-18. Although buprenorphine is not approved for use among people under the age of 16 in the U.S., some professional medical societies recommend that buprenorphine be considered as a treatment option for opioid use disorder in younger people.

“It is tragic to see that young people with opioid use disorder are unable to access buprenorphine in most treatment facilities, despite this medication being the standard of care for people aged 16 and older” said Nora Volkow, M.D., director of NIDA. “Residential treatment facilities provide an opportunity to reach young people with a range of evidence-based supports at a pivotal time in their lives, and it is crucial that buprenorphine is made available as one of those options.”

Residential treatment facilities are part of the continuum of care for adolescents with opioid use disorder. However, little is known about specific evidence-based treatment options offered to young people at these facilities, including medications for opioid use disorder. To address this gap, researchers at OHSU sought to determine how many adolescent treatment centers in the U.S. were offering buprenorphine to treat opioid use disorder.

Using the FindTreatment.gov database, which is maintained by the Substance Abuse and Mental Health Services Administration (SAMSHA), the researchers identified a list of 354 centers across the U.S. that offered treatment for “substance use,” in a “residential/24-hour residential” service setting, and for “children/adolescents” (defined as people aged 17 and younger) to include in the analysis.

Researchers called these facilities to inquire about treatment and services offered as potential users of these services for a 16-year-old with a recent non-fatal fentanyl overdose. Between October and December 2022, the study team called the facilities in a random order and confirmed that 160 (45%) of these facilities provided residential treatment to patients under the age of 18.

Of the 160 residential addiction treatment facilities found to provide treatment to young patients, the researchers found that 39 facilities (24%) said that they offered buprenorphine to patients aged 16 or older, including through partnership with outside prescribing clinicians, though specific parameters for offering buprenorphine varied by site. For instance, only 20 facilities (12.5%) said that they offered buprenorphine for ongoing treatment. 12 facilities (7.5%) said that they offered buprenorphine to adolescents under 16 years of age.

Among the other 121 facilities that did not offer buprenorphine to adolescents or weren’t sure, 57 (47%) indicated that adolescents prescribed buprenorphine by their own clinician could stay on it at least temporarily, although some stated they would discontinue it before discharge. And 27 (22%) required that adolescents were not taking buprenorphine in order to be admitted for residential treatment.

Based on these findings, the average person would need to call nine facilities on the SAMHSA list to find one that offered buprenorphine. To find one for an adolescent under 16, they would need to call 29 facilities.

“These residential treatment centers see some of the most vulnerable adolescents in our communities,” said lead author Caroline King, M.D., Ph.D., who completed this research as a student in the OHSU School of Medicine. “We need to support these centers to make evidence-based care the norm.”

“Buprenorphine is the one medication that’s approved for use in adolescents, and it’s underused in facilities taking care of kids with the most severe opioid use disorder,” said co-author Todd Korthuis, M.D., M.P.H., head of addiction medicine at OHSU. “It’s a big issue, but it’s something that we can change by supporting these treatment centers with education and technical assistance about buprenorphine, better funding to staff these centers, and by letting the public know that buprenorphine is necessary treatment in healing brains.”






TRUISM
👍️0
TRUISM TRUISM 10 months ago
Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder

Article/PR



BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses.

Patients currently on a transmucosal buprenorphine-containing product can be switched to an equivalent dose of BRIXADI Weekly or Monthly.

BRIXADI will be available through a restricted distribution program via the BRIXADI REMS Program and is administered only by a healthcare professional.

PLYMOUTH MEETING, Pa., May 23, 2023 /PRNewswire/ -- Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a transmucosal buprenorphine-containing product.

BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. BRIXADI is to be administered only by healthcare providers in a healthcare setting and will be available in the U.S. in September 2023.




BRIXADI is the first and only weekly and monthly subcutaneous injection for moderate to severe OUD and is the only buprenorphine injectable that utilizes FluidCrystal®* Injection Depot Technology. Patients currently being treated with oral buprenorphine-containing products can be switched to equivalent doses of BRIXADI Weekly or BRIXADI Monthly in accordance with the Prescribing Information for BRIXADI.

"Today's FDA approval of BRIXADI is a significant step forward in the fight against OUD," said Mike Derkacz, President and CEO of Braeburn. "Over the last three years the US experienced a significant increase in opioid overdoses in part related to the economic and social upheaval that negatively impacted all of us, especially people with opioid use disorder and people in recovery.

Additional medication options for opioid use disorder will support healthcare providers in addressing the needs of their patients with opioid use disorder."

Due to the risk of serious harm resulting from accidental intravenous (IV) administration, BRIXADI has a Boxed Warning and will be made available through a restricted distribution program called the BRIXADI Risk Evaluation and Mitigation Strategy (REMS). Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements. Information on the BRIXADI REMS program will be available at www.BRIXADIREMS.com.

BRIXADI is the only injectable buprenorphine studied against sublingual buprenorphine/naloxone (SL BPN/NX) in a 24-week Phase 3, double-blind study, which randomized 428 adults with moderate to severe OUD. The trial enrolled patients representative of the real-world population, including patients that injected opioids (52%), patients that primarily used heroin (71%), patients with evidence of fentanyl use (26%) and patients using nonopioid substances at screening (71%).

In this pivotal Phase 3 efficacy and safety trial, weekly and monthly BRIXADI met the primary endpoint of non-inferiority for responder rate versus daily SL BPN/NX (16.9% vs. 14.0%, respectively; p<0.001). Additionally, BRIXADI demonstrated superiority to SL BPN/NX based on the cumulative distribution function (CDF) of the percentage of negative opioid assessments from week 4 through week 24 (p=0.004; secondary endpoint).

"A weekly and monthly buprenorphine injection with different dose options can align with clinical practice and patient care needs," said Dr. Michelle Lofwall, Professor of Behavioral Science and Psychiatry at the University of Kentucky Center on Drug and Alcohol Research and Primary Investigator in the Phase 3 efficacy and safety study. "Some patients need help with taking their medication as prescribed, some prefer not taking a daily medication or visiting a pharmacy to pick up their medication, so having a weekly and monthly option that provides buprenorphine over one week or one month could benefit patients, their loved ones and the treatment providers."

The safety profile of BRIXADI was consistent with the known systemic safety profile of oral buprenorphine with the exception of mild-to-moderate injection-site reactions. The most common adverse reactions included injection-site pain, headache, constipation, nausea, injection-site erythema, injection-site pruritus, insomnia and urinary tract infections.

BRIXADI is formulated using FluidCrystal® Injection Depot Technology, allowing for a low volume pre-filled syringe. Upon injection and contact with fluids in the tissue, the solution transforms into a nanostructured liquid-crystalline gel allowing for a slow release of buprenorphine at a steady rate over a one-week or one-month period. BRIXADI is delivered with a 23-gauge needle and may be administered in the buttock, thigh, stomach (abdomen) or upper arm.** BRIXADI does not require refrigeration.

*FluidCrystal® is a trademark owned by Camurus and used under license by Braeburn.

**In patients who are not currently receiving buprenorphine treatment, for BRIXADI Weekly, the upper arm site should only be used after steady state has been achieved (4 weeks).

Always felt Braeburn wanted to bur Probuphine, in order to shelve it.

What's in the dark, surfaces to the light eventually.




TRUISM
👍️0
TRUISM TRUISM 1 year ago
May soon be experiencing deja vu all over again.





TRUISM
👍️0
TRUISM TRUISM 1 year ago
May soon be experiencing deja vu all over again.


Was just a matter of time until the share price dipped under $1.00.



TRUISM
👍️0
TRUISM TRUISM 2 years ago
Shaking things up a bit.

A necessary evil, if you will.





Activist Investing Nominates Slate Of Highly Qualified Director Candidates For Election To the Board Of Directors Of Titan Pharmaceuticals At Upcoming Special Meeting Of Stockholders


TRUISM
👍️0
TRUISM TRUISM 2 years ago
Activist Investing Nominates Slate Of Highly Qualified Director Candidates For Election To the Board Of Directors Of Titan Pharmaceuticals At Upcoming Special Meeting Of Stockholders

PR ANNOUNCEMENT


July 11 2022 - 08:00AM
GlobeNewswire Inc.




David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), one of the largest stockholders of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) with 25.2% of the Company’s outstanding shares, today issued the following statement:
“We have submitted a request for the Company to hold a special meeting of the Company’s stockholders (the “Special Meeting”) to expand the size of Titan’s Board of Directors (the “Board”) by six (6) directors and to elect our slate of six (6) highly qualified professionals, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, David E. Lazar, Matthew C. McMurdo and David Natan (collectively, the “Nominees”), to fill the resulting Board vacancies in order to progress the Company’s previously announced review of strategic alternatives.

The Nominees collectively possess decades of experience in strategic turnarounds, deal structuring, corporate governance, investment management, accounting, finance and corporate law, which we believe will be extremely additive to the Company and its ability to unlock significant stockholder value through a strategic transaction.

As disclosed by the Company, the Special Meeting will be held on August 2, 2022 with a corresponding record date of July 22, 2022 to determine the stockholders entitled to vote on our proposals at the Special Meeting. We look forward to communicating further with fellow stockholders in the coming weeks and will be filing proxy materials to solicit votes to materially reconstitute the Board at the Special Meeting with our Nominees.”

Biographies of Activist Investing’s nominees are included below:

We believe that Mr. Ben-Tzvi’s extensive legal experience and knowledge in the field of civil-commercial law, and in corporate and securities law, and his previous public company and commercial business experience will make him a valuable addition to the Board. Avraham Ben-Tzvi, Adv. is the Founder of ABZ Law Office, a boutique Israeli law firm specializing in outsourced general counsel services for publicly traded as well as private companies and corporations, Investments & Securities Laws, Commercial Law & Contracts and various civil law matters, which he established in January 2017. Mr. Ben-Tzvi served as Chief Legal Officer and General Counsel of Purple Biotech Ltd. (formerly Kitov Pharma Ltd.), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, from November 2015 until April 2020.

Prior to that, Mr. Ben-Tzvi served as General Counsel and secretary at Medigus Ltd., a minimally invasive endosurgical tools medical device and miniaturized imaging equipment company, from April 2014 until November 2015. Mr. Ben-Tzvi is a member of the Israel Bar Association, and is also licensed as a Notary by the Israeli Ministry of Justice. Prior to that he served as an attorney at one of Israel’s leading international law firms where, amongst other corporate and commercial work, he advised companies and underwriters on various offerings by Israeli companies listing in US and on various SEC related filings.

Prior to becoming a lawyer, Mr. Ben-Tzvi worked in a number of business development, corporate finance and banking roles at companies in the financial services, lithium battery manufacturing and software development industries. Mr. Ben-Tzvi holds a B.A., magna cum laude, in Economics from Yeshiva University in New York and an LLB, magna cum laude with Honors, in from Sha'arei Mishpat College of Law in Hod HaSharon, Israel.

We believe that Mr. Chasey’s commercial law expertise, coupled with his experience leading his own law firm, will make him a valuable addition to the Board. Peter L. Chasey, Esq. serves as the Owner of Chasey Law Offices, a law practice specializing in personal litigation, business litigation and commercial law, since founding the practice in 2005. Earlier in his career, Mr. Chasey served as staff counsel for one of the largest insurance companies in the world defending general claims against insured businesses and also served as a land surveyor. Mr. Chasey holds a B.S. in Political Science and Government from the University of San Diego and a J.D. from the University of San Diego School of Law.

We believe that Mr. Greenberg’s more than 40 years’ experience in trading, developing strategies, and portfolio management and public markets experience in the microcap sector will make him a valuable addition to the Board. Eric Greenberg has over 40 years of capital markets experience. As a trader and portfolio manager at hedge funds, his areas of expertise included the development of trading strategies, portfolio management and deal structuring.

Mr. Greenberg was Co-Founder of Blink Charging Co., a leader in the EV charging infrastructure industry. In addition, Mr. Greenberg provides investor relation and digital marketing services for companies across a variety of industries, such as life sciences, fintech, internet platforms and others. Mr. Greenberg holds a B.B.A in Finance from Baruch College and an M.B.A. in Finance from Baruch College Zicklin School of Business.

We believe Mr. Lazar’s position as a significant investor in the Company and his diverse knowledge of financial, legal and operations management, public company management, accounting, audit preparation, due diligence reviews and SEC regulations will make him a valuable addition to the Board. David E. Lazar has served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed public companies through custodianship, since February 2018, and Activist Investing LLC, an actively managed investment fund, since March 2018.

Previously, Mr. Lazar served as Managing Partner at Zenith Partners International Inc., a boutique consulting firm, from July 2012 to April 2018. In his role as Chief Executive Officer of Custodian Ventures LLC, Mr. Lazar has successfully served as a custodian to numerous public companies across a wide range of industries. Mr. Lazar currently serves as an Advisor to PROMAX Investments LLC, a position he has held since July 2022, and as an Ambassador at Large for the Arab African Council for Integration and Development, since March 2022.

We believe that Mr. McMurdo’s extensive experience in corporate and securities law and advising many public companies with federal securities law will make him a valuable addition to the Board. Matthew C. McMurdo, Esq. currently serves as Managing Member of McMurdo Law Group, LLC, a corporate and securities law practice, since 2010.

Previously, Mr. McMurdo was a Partner at Nannarone & McMurdo, LLP, a boutique law firm, from 2008 to 2010. In addition, Mr. McMurdo served as General Counsel of Berkley Asset Management LLC, the general partner of a real estate fund focused on opportunistic and distressed real estate assets, from 2011 to 2013. Mr. McMurdo holds a B.S. in Finance from Lehigh University and a J.D., cum laude, from Benjamin N. Cardozo School of Law.

We believe Mr. Natan’s reputation as a seasoned business executive and his extensive experience as a director of technology-enabled public companies will make him a valuable addition to the Board. David Natan currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of industries, since 2007. In addition, Mr. Natan currently serves as Executive Vice President and Chief Financial Officer for Airborne Motorworks, Inc., a privately-held aerospace transportation company, since April 2020.

From February 2010 to May 2020, Mr. Natan served as Chief Executive Officer of ForceField Energy, Inc., a company focused on the solar industry and LED lighting products. From February 2002 to November 2007, Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of PharmaNet Development Group, Inc., a drug development services company, and, from June 1995 to February 2002, as Chief Financial Officer and Vice President of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and speakers and speaker components.

Prior to that, Mr. Natan served in various roles of increasing responsibility with Deloitte & Touche LLP, a global consulting firm. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of Global Diversified Marketing Group, Inc., a manufacturer, marketer and distributor of food and snack products, since February 2021 and serves as a member of the Board of Directors and Chair of the Audit Committee of Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, since February 2022.

Previously, Mr. Natan served as Chairman of the Board of Directors of ForceField Energy, Inc., from April 2015 to May 2020, and as a member of the Board of Directors of Global Technovations, Inc., from December 1999 to December 2001. Mr. Natan holds a B.A. in Economics from Boston University.

About Activist Investing

Activist Investing LLC is an investment fund specializing in reverse merger and other event-driven opportunities. Its Chief Executive Officer, David E. Lazar, brings domestic and international experience in operations, accounting, audit preparation, due diligence, capital restructuring, debt financing, and mergers and acquisitions.

Certain Information Concerning the Participants

Activist Investing LLC (“Activist Investing”), together with the other participants named herein (collectively, “Activist”), intends to file a preliminary proxy statement and an accompanying WHITE proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of its slate of highly-qualified director nominees and in connection with the related proposals to be acted upon by stockholders at the upcoming special meeting of stockholders of Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”).

ACTIVIST STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING A WHITE PROXY CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO ACTIVIST INVESTING.

The participants in the proxy solicitation are expected to be Activist Investing, David E. Lazar, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, Matthew C. McMurdo and David Natan (collectively, the “Participants”).

As of the date hereof, Activist Investing directly beneficially owns 359,066 shares of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). As of the date hereof,

Mr. Lazar directly beneficially owns 3,331,402 shares of Common Stock. Mr. Lazar, as the sole member and Chief Executive Officer of Activist Investing, may be deemed to beneficially own the 359,066 shares of Common Stock directly beneficially owned by Activist Investing. As of the date hereof, none of Messrs. Ben-Tzvi, Chasey, Greenberg, McMurdo or Natan beneficially owns any shares of Common Stock.

Investor Contact Information:
David E. Lazar
David@activistinvestingllc.com





TRUISM
👍️0
TradeSmart.ai TradeSmart.ai 2 years ago
Yes sir
👍️0
TRUISM TRUISM 2 years ago
A sleeping giant ten bagger you say?

Time will tell; stranger things have happened.


$TTNP 5 Mil Float - Current $1.32 / ATH $11



TRUISM
👍️0
TradeSmart.ai TradeSmart.ai 2 years ago
$TTNP 5 Mil Float - Current $1.32 / ATH $11
👍️0
TRUISM TRUISM 2 years ago
There's definitely money to be made; for now.

Should be 1st Green Day spikes ;))$$




TRUISM
👍️0
airman1 airman1 2 years ago
Should be 1st Green Day spikes ;))$$
👍️0
TRUISM TRUISM 2 years ago
The supposition presented does not pertain to my particular investment situation

regarding this company..

It is what it is.


We're all makin bank! Sorry for your loss!



TE
👍️0
TRUISM TRUISM 2 years ago
They had a chance to do big things with Braeburn Pharma, back when.

Sorry but it comes off as a "redo" to me.

There's not much faith in stagnation.

What happened to their previous venture?

Follow the breadcrumbs.

Daytraders ran this up.

Watch the coming days and weeks.

That will speak for itself.


TE
👍️0
crudeoil24 crudeoil24 2 years ago
We're all makin bank! Sorry for your loss !

TTNP
👍️0
crudeoil24 crudeoil24 2 years ago
FDA clearance today is a catalyst for a merger opportunity.

TTNP
👍️0
TRUISM TRUISM 2 years ago
Because everything done up to this point, has worked so well.

Check the history, with potential funding, to boot.

What's going to be so different this time around?

This company has disappointed more than locating a closed amusement park, on a child's birthday..


developing a novel product that may help answer the call for long-term treatment options in addiction medicine.



TE
👍️0
crudeoil24 crudeoil24 2 years ago
Titan Pharmaceuticals Gets FDA Clearance To Commence Opioid Disorder Study

The U.S. Food and Drug Administration (FDA) has cleared Titan Pharmaceuticals’ (NASDAQ: TTNP) Investigational New Drug (IND) application for the Phase 1 study of its drug candidate Nalmefene.

The Phase 1 study will investigate six-month or longer subdermal formulation of nalmefene intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder (OUD).

Kate Beebe DeVarney, President and Chief Operating Officer of Titan, commented, "FDA clearance of the IND for our ProNeura®-based nalmefene implant marks an important milestone in developing a novel product that may help answer the call for long-term treatment options in addiction medicine. We are very grateful for the support we received from the National Institute for Drug Addiction, or NIDA, that enabled us to meet this objective.”
👍️0
TRUISM TRUISM 2 years ago
Was just a matter of time until the share price dipped under $1.00.



TTE
👍️0
Afterhoursearnings3 Afterhoursearnings3 2 years ago
Yeap, the product solved a really important problem and then got buried by Sunil and gang. Disappointing to say the least.
👍️0
TRUISM TRUISM 2 years ago
Just feel bad for the past investors, who really were behind the product.



TRUTH
👍️0
TRUISM TRUISM 2 years ago
Definite potential over the years.

Such a great need for diversion-proof OUD treatments like probuphine.


========================

Why don't Bill and Melinda Gates have an overseer for TTNP?


Of course, Titan screwed it up pretty badly too. But FDA made it VERY difficult for Titan to succeed. Other, bigger pharmas seemed to have it much easier for their OUD treatments.



TRUTH
👍️0
KMBJN KMBJN 2 years ago
Such a great need for diversion-proof OUD treatments like probuphine.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785011

https://www.hhs.gov/about/news/2021/04/27/hhs-releases-new-buprenorphine-practice-guidelines-expanding-access-to-treatment-for-opioid-use-disorder.html

HHS in April relaxed some of the onerous requirements for using buprenorphine for OUD, but somehow FDA really screwed Titan by making probuphine so difficult to use in practice. They massively limited which patients were eligible, made re-implantation difficult, burdened the company with post-marketing studies, etc... If they really want to expand access, what is the harm in letting everyone get the diversion proof probuphine implant as needed? Too bad Titan couldn't apply for a label expansion since there really is such a strong need to expand access to probuphine. What is easier than a quick procedure every 6 months to get a new implant?

Of course, Titan screwed it up pretty badly too. But FDA made it VERY difficult for Titan to succeed. Other, bigger pharmas seemed to have it much easier for their OUD treatments.

👍️0
TRUISM TRUISM 2 years ago
Wonder if there are any timelines or additional stipulations, that go with acceptance of said grant.

Given Titan's sordid history.

At any rate, they'll be watched closely.

It will still need approval.

Would be something if the B & M Gates foundation would commit to purchasing X amount, once approved in select countries.



TRUTH
👍️0
TRUISM TRUISM 2 years ago
So produce an refractive, yet cheaper version of the pro-neura system.


TRUTH
👍️0
TRUISM TRUISM 2 years ago
They don't even include the specific amount of the grant.

Suppose the next quarterly filing will include this.

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to deliver a human immunodeficiency virus ("HIV") preventative therapeutic and a contraceptive from a single implant using its proprietary ProNeura(R) technology, and ensure this technology is accessible to women and adolescent girls in low- and middle-income countries.


TRUTH

👍️0
TRUISM TRUISM 2 years ago
They'll mess that up too.

Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries




TRUTH
👍️0
Dr. Johnny Fever Dr. Johnny Fever 2 years ago
Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries
7:15 am ET October 25, 2021 (PR Newswire) Print
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to deliver a human immunodeficiency virus ("HIV") preventative therapeutic and a contraceptive from a single implant using its proprietary ProNeura(R) technology, and ensure this technology is accessible to women and adolescent girls in low- and middle-income countries.

https://mma.prnewswire.com/media/472621/titan_logo_2016_copy_Logo.jpg

"Reducing the burden of HIV, while simultaneously increasing access to contraceptive options, could have a major impact on the health of women and adolescent girls in low- and middle-income countries," said Marc Rubin, M.D., Executive Chairman of Titan. "We believe that our ProNeura platform is uniquely suited to this program, as we have demonstrated the feasibility of long-term delivery of two pharmaceutically active ingredients from a single implant in an earlier development program. The continuous long-term delivery of a contraceptive/antiviral combination has the potential to have a greater public health impact in developing nations, compared with daily dosing of multiple compounds."

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura(R) long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT:

Stephen Kilmer Investor Relations(650) 989-2215 skilmer@titanpharm.com

https://c212.net/c/img/favicon.png?sn=SF50375&sd=2021-10-25

View original content to download multimedia:https://www.prnewswire.com/news-releases/titan-pharmaceuticals-receives-funding-to-develop-combination-hiv-therapeutic-and-contraceptive-implant-for-women-in-developing-countries-301407256.html

SOURCE Titan Pharmaceuticals, Inc.

https://rt.prnewswire.com/rt.gif?NewsItemId=SF50375&Transmission_Id=202110250715PR_NEWS_USPR_____SF50375&DateId=20211025

👍️0
TRUISM TRUISM 2 years ago
There was once so much promise here.




TRUTH
👍️0
TRUISM TRUISM 3 years ago
Was hoping new management would bring a change.

Don't want to think it's all about the paycheck.

Time will tell, either way, as interest appears to be dissipating.



TRUTH
👍️0
TRUISM TRUISM 3 years ago
Volume is decreasing with time.

Here's to hoping TTNP will issue a PR in the foreseeable future....

Something worthy of affecting the share price; in a good way.




TRUTH
👍️0
TRUISM TRUISM 3 years ago
“Dealers are lacing these non-opioid drugs with cheaper, yet potent, opioids to make a larger profit,” she said. “Someone who’s addicted to a stimulant drug like cocaine or methamphetamine is not tolerant to opioids, which means they are going to be at high risk of overdose if they get a stimulant drug that’s laced with an opioid like fentanyl.”

The surging death rate eclipses modest gains made during President Trump’s term against the nation’s entrenched addiction epidemic. During his administration, several billion dollars in grants to states allowed more drug users to get access to the three F.D.A.-approved medications for opioid addiction — methadone, buprenorphine and naltrexone — that work by suppressing cravings and symptoms of withdrawal. Naloxone, the overdose-reversing drug that has saved thousands of lives, also became widely distributed.



TRUTH
👍️0
TRUISM TRUISM 3 years ago
The preliminary data released Wednesday by the Centers for Disease Control and Prevention show a 29 percent rise in overdose deaths from October 2019 through September 2020 — the most recent data available — compared with the previous 12-month period. Illicitly manufactured fentanyl and other synthetic opioids were the primary drivers, although many fatal overdoses have also involved stimulant drugs, particularly methamphetamine.

And unlike in the early years of the opioid epidemic, when deaths were largely among white Americans in rural and suburban areas, the current crisis is affecting Black Americans disproportionately.




TRUTH
👍️0
TRUISM TRUISM 3 years ago
More than 87,000 Americans died of drug overdoses over the 12-month period that ended in September, according to preliminary federal data, eclipsing the toll from any year since the opioid epidemic began in the 1990s.

The surge represents an increasingly urgent public health crisis, one that has drawn less attention and fewer resources while the nation has battled the coronavirus pandemic.



TRUTH
👍️0
TRUISM TRUISM 3 years ago
Overdose Deaths Have Surged During The Pandemic, C.D.C. Data Shows-By Abby Goodnough-April 14, 2021
Click For NY Times Article


The latest numbers surpass even the yearly tolls during the height of the opioid epidemic and mark a reversal of progress against addiction in recent years.




Firefighters and paramedics tended to a person who went into cardiac arrest after a drug overdose in Brooklyn, Md., last year.Credit...Alex Edelman/Agence France-Presse — Getty Images



WASHINGTON — More than 87,000 Americans died of drug overdoses over the 12-month period that ended in September, according to preliminary federal data, eclipsing the toll from any year since the opioid epidemic began in the 1990s.

The surge represents an increasingly urgent public health crisis, one that has drawn less attention and fewer resources while the nation has battled the coronavirus pandemic.

Deaths from overdoses started rising again in the months leading up to the coronavirus pandemic — after dropping slightly in 2018 for the first time in decades — and it is hard to gauge just how closely the two phenomena are linked. But the pandemic unquestionably exacerbated the trend, which grew much worse last spring: The biggest jump in overdose deaths took place in April and May, when fear and stress were rampant, job losses were multiplying and the strictest lockdown measures were in effect.

Many treatment programs closed during that time, at least temporarily, and “drop-in centers” that provide support, clean syringes and naloxone, the lifesaving medication that reverses overdoses, cut back services that in many cases have yet to be fully restored.

The preliminary data released Wednesday by the Centers for Disease Control and Prevention show a 29 percent rise in overdose deaths from October 2019 through September 2020 — the most recent data available — compared with the previous 12-month period. Illicitly manufactured fentanyl and other synthetic opioids were the primary drivers, although many fatal overdoses have also involved stimulant drugs, particularly methamphetamine.

And unlike in the early years of the opioid epidemic, when deaths were largely among white Americans in rural and suburban areas, the current crisis is affecting Black Americans disproportionately.

“The highest increase in mortality from opioids, predominantly driven by fentanyl, is now among Black Americans,” Dr. Nora Volkow, the director of the National Institute on Drug Abuse, said at a national addiction conference last week. “And when you look at mortality from methamphetamine, it’s chilling to realize that the risk of dying from methamphetamine overdose is 12-fold higher among American Indians and Alaskan Natives than other groups.”

Dr. Volkow added that more deaths than ever involved drug combinations, typically of fentanyl or heroin with stimulants.

“Dealers are lacing these non-opioid drugs with cheaper, yet potent, opioids to make a larger profit,” she said. “Someone who’s addicted to a stimulant drug like cocaine or methamphetamine is not tolerant to opioids, which means they are going to be at high risk of overdose if they get a stimulant drug that’s laced with an opioid like fentanyl.”

The surging death rate eclipses modest gains made during President Trump’s term against the nation’s entrenched addiction epidemic. During his administration, several billion dollars in grants to states allowed more drug users to get access to the three F.D.A.-approved medications for opioid addiction — methadone, buprenorphine and naltrexone — that work by suppressing cravings and symptoms of withdrawal. Naloxone, the overdose-reversing drug that has saved thousands of lives, also became widely distributed.

Brendan Saloner, an associate professor at the Johns Hopkins School of Public Health who studies access to addiction treatment, said surveys that he and a colleague, Susan Sherman, conducted of drug users and people in treatment in 11 states during the pandemic found that many had used drugs more often during that time — and used them alone more often, likely because of lockdowns and social distancing. Well over half the participants also said the drugs they used had been cut or mixed more than usual, another red flag.

“The data points corroborate something I believe, which is that people who were already using drugs started using in ways that were higher risk — especially using alone and from a less reliable supply,” Dr. Saloner said.



A vigil remembering people who died of drug overdoses in Gloucester, Mass., in August.Credit...CJ Gunther/EPA, via Shutterstock


Although President Biden has yet to appoint a permanent “drug czar,” his Office of National Drug Control Policy released an outline last week of its priorities for addressing the addiction and overdose epidemic. They include measures the Trump administration also embraced, like expanding access to medication treatment for opioid addiction, but diverged from the Trump agenda by pledging to address “systemic inequities” in prevention, treatment and recovery.

And although the Biden plan embraced medications for addiction, shortly after his inauguration, Mr. Biden reversed a move by the Trump administration that would have made it easier for doctors to prescribe buprenorphine, a lifesaving anti-craving medication, for opioid addiction.

Members of the new administration said at the time that the plan was not legally sound, but one of the priorities listed in the new document is to “remove unnecessary barriers to prescribing buprenorphine.”

On Tuesday, several dozen organizations that work on addiction and other health issues asked Mr. Biden’s health and human services secretary, Xavier Becerra, to “act with urgency” and eliminate the rule that doctors go through a day of training before getting federal permission to prescribe buprenorphine. Many addiction experts are also calling for abolishing rules that had already been relaxed during the pandemic so that patients don’t have to come to clinics or doctors’ offices for addiction medications.

Although many programs offering treatment, naloxone and other services for drug users have reopened at least partly as the pandemic has dragged on, many others remain closed or severely curtailed, particularly if they operated on a shoestring budget to begin with.

Sara Glick, an assistant professor of medicine at the University of Washington, said a survey of about 30 syringe exchange programs that she conducted last spring found that many closed temporarily early in the pandemic. After reopening, she said, many programs cut back services or the number of people they could help.

“With health departments spending so much on Covid, some programs have really had to cut their budgets,” she said. “That can mean seeing fewer participants, or pausing their H.I.V. and hepatitis C testing.”

At the same time, increases in H.I.V. cases have been reported in several areas of the country with heavy injection drug use, including two cities in West Virginia, Charleston and Huntington, and Boston. West Virginia’s legislature passed a law last week placing new restrictions on syringe exchange programs, which advocates of the programs said would force many to close.

Mr. Biden’s American Rescue Plan Act includes $1.5 billion for the prevention and treatment of substance use disorders, as well as $30 million in funding for local services that benefit people with addiction, including syringe exchange programs.

The latter is significant because while federal funds still largely cannot be spent on syringes for people who use drugs, the restriction does not apply to money from the stimulus package, according to the Office of Drug Control Policy. Last week, the administration announced that federal funding could now be used to buy rapid fentanyl test strips, which can be used to check whether drugs have been mixed or cut with fentanyl.

Fentanyl or its analogues have increasingly been detected in counterfeit pills being sold illegally as prescription opioids or benzodiazepines — sedatives like Xanax that are used as anti-anxiety medications — and particularly in meth.

Northeastern states that had been hit hardest by opioid deaths in recent years saw some of the smallest increases in deaths in the first half of the pandemic year, with the exception of Maine. The hardest-hit states included West Virginia and Kentucky, which have long ranked at the top in overdose deaths, but also western states like California and Arizona and southern ones like Louisiana, South Carolina and Tennessee.


Abby Goodnough is a national health care correspondent. She has also served as bureau chief in Miami and Boston, and covered education and politics in New York City. She joined The Times in 1993. @abbygoodnough





TRUTH
👍️0
Taurus69 Taurus69 3 years ago
$ttnp $2.75 v -0.1 (-3.51%)
Volume: 282,201 @03/26/21 7:44:00 PM EDT
👍️0
interstate interstate 3 years ago
👍️0
Trichrome Trichrome 3 years ago
Why the hell did I buy this piece of crap stock? Or better yet, why haven't I eaten the loss yet and given the rest to a homeless person?
👍️0
Taurus69 Taurus69 3 years ago
$ttnp $3.3799 ^ 0.0399 (1.19%)
Volume: 1,166,861 @02/26/21 7:56:49 PM EST
👍️0

Your Recent History

Delayed Upgrade Clock